Search the Newsreel

Sprott: Gold and Silver Correction Cyclical, Long-Term Bull Market Intact | 2026 Outlook - News and Statistics

Sprott Inc. views the recent decline in precious metals as a temporary, cyclical correction within an ongoing long-term bull market, not a reversal of the trend. Maria Smirnova, Managing Partner at Sprott, attributes the pullback to cyclical factors rather than weakening fundamentals, emphasizing that …

PTGX (PTGX) insider files to sell 225,000 shares under Rule 144

An insider at Protagonist Therapeutics (PTGX) has filed to sell 225,000 common shares under Rule 144, with an aggregate market value of $33,583,500. The sale will be executed through J.P. Morgan Securities LLC on Nasdaq and is associated with an option exercise. This filing …

Price correction ‘improved the long-term risk-reward profile’ for both gold and silver – Sprott’s Smirnova

Maria Smirnova of Sprott Inc. stated that the recent price correction in gold and silver was a cyclical adjustment within a secular bull market, not a reversal. She highlighted that underlying macroeconomic factors like rising debt, central bank buying, and geopolitical fragmentation continue to …

Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating

Wedbush has increased its price target for Protagonist Therapeutics (PTGX) to $173 from $118, while maintaining an Outperform rating on the stock. This adjustment reflects a more optimistic outlook from the analyst firm.

Prothena 10% owner William P. Scully buys $293,052 of common shares

William P. Scully, a 10% owner of Prothena, recently purchased 34,000 ordinary shares for $293,052, increasing his direct stake to 790,000 shares. Additionally, Manatee Equity Fund LLC, attributed to Scully, acquired 3,500 shares. Scully's spouse also holds 52,000 ordinary shares indirectly.

Understanding Momentum Shifts in (FUND)

This article analyzes Sprott Focus Trust Inc. (NASDAQ: FUND), highlighting a mid-channel oscillation pattern and a strong 17.0:1 risk-reward setup. It outlines three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles, along with multi-timeframe signal analysis, suggesting strong …

What Makes Proto Labs (PRLB) a Strong Momentum Stock: Buy Now?

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

Apogee Adds Joseph Hayek, Suresh Krishna to Board of Directors

Apogee Enterprises Inc. has expanded its board of directors from six to eight members by electing Joseph Hayek and Suresh Krishna as independent directors. Hayek is the president and CEO of Worthington Enterprises Inc., and Krishna is the president and CEO of Proto Labs …

Proto Labs (PRLB) Lifts Outlook As Fair Value Looks Fully Valued

Protagonist upgraded at Goldman Sachs on potential of autoimmune asset

Goldman Sachs upgraded Protagonist Therapeutics (PTGX) to a buy rating from neutral, setting a price target of $186. The upgrade is driven by the promising potential of the company's phase 1 oral IL-17 antagonist, PN-881, which is being developed for various autoimmune conditions. This …

Goldman Sachs Upgrades Protagonist Therapeutics to Buy From Neutral, Adjusts PT to $186 From $110

Goldman Sachs has upgraded Protagonist Therapeutics (PTGX) to a "Buy" rating from "Neutral" and increased its price target to $186 from $110. The article also notes that Protagonist Therapeutics has an average rating of "Buy" and a mean price target of $159.36 from other …

PROTAGONIST THERAPEUTICS, INC. : WEDBUSH RAISES TARGET PRICE TO $173 FROM $118

Wedbush has increased its target price for Protagonist Therapeutics, Inc. to $173, up from the previous $118. The information is provided by Reuters and indicates a significant positive revision in the analyst's outlook for the company's stock.

Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating

Truist has raised its price target for Protagonist Therapeutics (NASDAQ: PTGX) from $145 to $170, while maintaining a "Buy" rating on the stock. This adjustment reflects a continued positive outlook from the firm on the biopharmaceutical company. Other analysts, including Goldman Sachs and Wedbush, …

Goldman Sachs upgrades Protagonist Therapeutics stock rating on drug potential

Goldman Sachs upgraded Protagonist Therapeutics (NASDAQ:PTGX) to Buy from Neutral, raising its price target to $186 from $110, citing the potential of its oral IL-17 drug, PN-881. The company recently reported strong Q2 2026 financial results, including significant license and collaboration revenue and a …

Sprott (TSX:SII) Is Up 14.0% After Rare Earths ETF-Fueled Earnings Beat Has The Bull Case Changed?

Protagonist Therapeutics (PTGX) Swings To Net Income, Is The Valuation Too Expensive?

Protagonist Therapeutics (PTGX) recently reported a swing to net income of US$162.85 million in Q2 2026, leading to significant share price momentum. Despite a high Price-to-Earnings ratio of 113.8x compared to industry averages, driven by strong future earnings growth forecasts, the company's Discounted Cash …

Proto Labs’s Q2 Earnings Call: Our Top 5 Analyst Questions

Proto Labs's Q2 Earnings Call: Our Top 5 Analyst Questions Proto Labs' second quarter was marked by expanding relationships with large enterprise customers and robust growth in both Injection Molding and CNC Machining services. Management credited the company's focus on its four strategic pillars—elevating …

Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA

Renaissance Technologies LLC increased its stake in Prothena Corporation plc (NASDAQ:PRTA) by 39.5% during the first quarter, now holding 607,515 shares valued at approximately $5.91 million. Institutional investors own 97.08% of the stock, while insiders have recently sold shares but also acquired a significant …

Prothena Corporation PLC (PRTA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Prothena Corporation PLC (PRTA) has an earnings forecast score of 6.67, ranking 318th in the Biotechnology & Medical Research industry. Analysts have an average price target of $18.50 for PRTA, with expectations for the next quarter's revenue at $11.51M and EPS at -$0.24. The …

Head-To-Head Survey: Sprott (NYSE:SII) & CompoSecure (NASDAQ:CMPO)

This article provides a head-to-head comparison of Sprott (NYSE:SII) and CompoSecure (NASDAQ:CMPO), two small-cap finance companies. The analysis covers profitability, earnings, dividends, risk, valuation, analyst recommendations, and institutional ownership. While Sprott shows higher earnings, CompoSecure has a stronger consensus rating and higher potential upside …

Proto Labs Inc (PRLB) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Shareholders Can Be Confident That Proto Labs' (NYSE:PRLB) Earnings Are High Quality

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

Why Protagonist Therapeutics (PTGX) Is Up 6.8% After Swinging to Q2 Profitability and Expanding ESOP

Prothena Corporation PLC (PRTA) Stock News Today

This article provides current stock information for Prothena Corporation PLC (PRTA), including its stock price, market capitalization, and a note that more news will be coming soon. It also lists various sections available on the TradingKey platform for PRTA, such as financials, stock score, …

Protagonist Therapeutics (NASDAQ:PTGX) Rating Lowered to Buy at Wall Street Zen

Wall Street Zen has downgraded Protagonist Therapeutics (NASDAQ:PTGX) from a "strong buy" to a "buy" rating. Despite this, the broader analyst consensus remains a "Moderate Buy" with an average price target of $126.71. The company recently reported strong quarterly earnings, beating estimates with $2.29 …

Proto Labs Inc (PRLB) Aktuelle Aktien-News

Empowered Funds LLC Takes $1.52 Million Position in Sprott Inc. $SII

Why Proto Labs (PRLB) Is Up 18.5% After Raising 2026 Guidance And Expanding ESOP Share Offering

Sprott (NYSE:SII) Stock Rating Lowered by Wall Street Zen

Sprott Inc (SII) (Q2 2026) Earnings Call Highlights: Record Adjusted EBITDA and Strategic ...

This article first appeared on GuruFocus. Assets Under Management (AUM): $55.6 billion as of June 30, 2026, down 15% from $65.1 billion at March 31, 2026, and down 7% from $59.6 billion at December 31, 2025. Average AUM: $63.9 billion for the quarter, up …

Proto Labs (PRLB) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Suresh KrishnaChief Financial Officer - Dan SchumacherInvestor Relations - Ryan Johnsrud TAKEAWAYS Revenue -- $149.3 million, up 10.2% in constant currency, representing …

Sprott Inc (SII) (Q2 2026) Earnings Call Highlights: Record Adjusted EBITDA and Strategic ... By GuruFocus

Sprott Inc. reported record Adjusted EBITDA of $50.8 million for Q2 2026, doubling from the prior year, despite a 15% quarter-over-quarter decrease in Assets Under Management (AUM) to $55.6 billion, largely due to a correction in precious metals prices. The company saw strong performance …

Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise

Prothena (PRTA) shares saw a modest 2.1% increase despite a significant drop in Q2 2026 collaboration revenue and a return to a net loss. Investors appear to be focused on the company's late-stage pipeline, including two Phase III programs, rather than recent financial results. …

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

Prothena Corporation plc reported its second quarter and first six months 2026 financial results, highlighting a net cash used in operating and investing activities of $25.7 million for the quarter and a net cash provided of $3.2 million for the first six months. The …

Prothena Corporation plc (PRTA) stock price, news, quote and history

This Yahoo Finance page provides a comprehensive overview of Prothena Corporation plc (PRTA) stock, including its current price, historical data, and key financial metrics. It details the company's clinical-stage biotechnology pipeline, focusing on therapies for protein dysregulation diseases, and offers analyst insights and performance …